Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Loriot

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
ESMO Open|August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinomaM S van der Heijden, T Powles, S Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) studyA Bayle, L Belcaid, M Aldea, et al.
ESMO Open|November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanomaJ Y Blay, C Cropet, S Mansard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
ESMO Open|August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinomaM S van der Heijden, T Powles, S Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) studyA Bayle, L Belcaid, M Aldea, et al.
ESMO Open|November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanomaJ Y Blay, C Cropet, S Mansard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 8